Early safety test of iCP-NI drug halted before completion
NCT ID NCT05740280
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase study tested the safety and tolerability of an experimental drug called iCP-NI in 24 healthy adults. Participants received either the drug or a placebo by intravenous infusion. The trial was terminated, so no conclusions about effectiveness can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- iCP-NI (improved cell-permeable nuclear import inhibitor)
- What could go wrong
- This was an early safety study in healthy people, so it cannot show if the drug works for any disease. The trial was terminated, meaning results may be incomplete.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Labcorp Clinical Research Unit Inc.
Daytona Beach, Florida, 32117, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults